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Background: New alternatives for the treatment of Tuberculosis (TB) are urgently needed and medicinal plants
represent a potential option. Chamaedora tepejilote and Lantana hispida are medicinal plants from Mexico and their
hexanic extracts have shown antimycobacterial activity. Bioguided investigation of these extracts showed that the
active compounds were ursolic acid (UA) and oleanolic acid (OA).
Methods: The activity of UA and OA against Mycobacterium tuberculosis H37Rv, four monoresistant strains, and
two drug-resistant clinical isolates were determined by MABA test. The intracellular activity of UA and OA against
M. tuberculosis H37Rv and a MDR clinical isolate were evaluated in a macrophage cell line. Finally, the antitubercular
activity of UA and OA was tested in BALB/c mice infected with M. tuberculosis H37Rv or a MDR strain, by determining
pulmonary bacilli loads, tissue damage by automated histomorphometry, and expression of IFN-γ, TNF-α, and iNOS
by quantitative RT-PCR.
Results: The in vitro assay showed that the UA/OA mixture has synergistic activity. The intracellular activity of these
compounds against M. tuberculosis H37Rv and a MDR clinical isolate in a macrophage cell line showed that both
compounds, alone and in combination, were active against intracellular mycobacteria even at low doses. Moreover,
when both compounds were used to treat BALB/c mice with TB induced by H37Rv or MDR bacilli, a significant
reduction of bacterial loads and pneumonia were observed compared to the control. Interestingly, animals treated
with UA and OA showed a higher expression of IFN-γ and TNF-α in their lungs, than control animals.
Conclusion: UA and OA showed antimicrobial activity plus an immune-stimulatory effect that permitted the control
of experimental pulmonary TB.
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At present, Tuberculosis (TB) is the only infectious disease
considered by the World Health Organization (WHO)
as a health emergency worldwide, because it causes nearly
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distribution, and reproduction in any mediumdeveloping countries and its association with human im-
munodeficiency virus (HIV)/acquired immunodeficiency
syndrome (AIDS) renders its control more difficult. In
addition, the emergence of multidrug-resistant tubercu-
losis (MDR-TB, defined as those TB strains simultan-
eously resistant at least to rifampin and isoniazid) and
extensively drug resistant tuberculosis strains (XDR-TB)
threaten the success of the directly observed therapy
short course (DOTS) and DOTS-Plus treatment programs
established by the WHO [2]. Despite all the progress
achieved, only one third of patients with TB receive ad-
equate treatment; in the case of MDR, few patients haveed Central Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,














Figure 1 Chemical structure of Ursolic acid (UA) and Olenolic
acid (OA).
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MDR-TB cases respond to the current treatment [1,2].
Since the release of rifampicin in 1976, only rifabutin
and rifapentin have been approved for TB treatment;
unfortunately, these drugs are not yet widely distributed
[3]. At present, a number of drugs are under investigation,
but only a few compounds are found in preclinical and
clinical evaluation (about 10 compounds) [1-4]. Thus,
there is an urgent need to discover new antituberculous
agents that are effective in the treatment of MDR cases
and also novel agents that can shorten the long conven-
tional chemotherapy in drug-sensitive TB. Within this
context, not only new synthetic drugs, but also natural
products from medicinal plants are potential sources of
new anti-mycobacterial products.
Chamaedora tepejilote (C. tepejilote) and Lantana hispida
(L. hispida) are widely distributed plants in Mexico known as
“tepejilote, palmita or palma camaedor” and “cinco negritos
or verbena” respectively, both plants have been used in
Mexican traditional medicine. Some of their common uses
include the treatment of respiratory complaints such as
cough, bronchitis, colds and pneumonia [5]. We have
previously reported that the hexanic fractions from these
plants had in vitro antimycobacterial activity and their
bioguided fractionation showed that the triterpenic com-
pounds ursolic acid (UA) and oleanolic acid (OA) were the
specific agents involved in this activity [6-8]. This effect has
been confirmed by other authors [9-11]. These triterpenic
acids also have antibacterial [12,13], antiviral [14], anti-
parasitic [13], antioxidant [15] and antitumoral activities
[16], as well as hepatoprotector [17] and gastroprotector
[18] effects. Interestingly, UA enhances the production of
nitric oxide (NO) and tumor necrosis factor alpha (TNF-α)
by activating nuclear factor-kappaB (NF-κB) in mouse mac-
rophages [19,20] and blocking transforming growth factor-
beta 1 (TGF-β1) activity [21,22]. The stimulation of NO
and TNF-α contributes to their immunoregulatory and
antitumoral effects, and could be significant in an immu-
notherapeutic agent against M. tuberculosis. In this study,
we report the in vitro antimycobacterial activity of UA and
OA isolated from the hexanic extract of the aerial parts of
C. tepejilote and L. hispida, against the reference drug-
sensitive M. tuberculosis strain H37Rv, monoresistant
H37Rv strains, several MDR clinical isolates and a group
of nontuberculous mycobacteria. The antitubercular ac-
tivity of both compounds was then confirmed in a well-
characterized murine model of progressive pulmonary TB.
Our results show therapeutic activity attributable to a com-
bination of bactericidal and immunotherapeutic effects.
Methods
Chemical compounds
Bioguided fractionation of the hexanic extracts from
C. tepejilote and L. hispida aerial parts yielded UA andOA, respectively [6-8]. The plant material was botanically
identified by Abigail Aguilar MSc and a voucher of each
specimen were deposited at the IMSSM Herbarium with
code number 13402 (L. hispida) and 140321 (C. tepejilote).
Both compounds (Figure 1) were structurally characterized
by spectroscopic and spectrometric data as compared with
those previously reported [23,24].In vitro antimycobacterial assay
The antimycobacterial activity of the triterpenic acids
was evaluated against the M. tuberculosis H37Rv (ATCC
27294) reference strain (a pan-sensitive strain) and against
four monoresistant strains of M. tuberculosis H37Rv
[streptomycin-resistant (ATCC 35820), isoniazid-resistant
(ATCC 35822), ethambutol-resistant (ATCC 35837) and
rifampicin-resistant (ATCC 35838)]. The microorganisms
were cultured up to log phase growth at 37°C in
Middlebrook 7H12 broth supplemented with 0.2% gly-
cerol and enriched with 10% Oleic acid-albumin, dextrose
and catalase (OADC) and further diluted to 1:20. Anti-
mycobacterial activity was determined by using the
microplate alamar blue assay (MABA), as previously de-
scribed [7,8]. In addition, the effect of both terpenoids was
also determined against a MDR M. tuberculosis strain
MTY 147 (resistant to isoniazid, rifampicin, ethambutol,
and ethionamide) and against a drug-resistant M. tubercu-
losis strain coded as MMDO that is resistant to isoniazid
and ethambutol and five non-tuberculous mycobacteria
(M. avium, M. smegmatis, M. simiae, M. chelonae and
M. fortuitum). The compounds were tested at a con-
centration of 2 mg mL-1 in 20% DMSO in Middlebrook
7H9 broth.In vitro determination of the synergistic antimycobacterial
activity of triterpenic acids
The pharmacological synergy of UA and OA was evalu-
ated against M. tuberculosis H37Rv by a modification of
the MABA assay [25]. Briefly, a stock solution of each
compound was prepared in 7H9 broth containing 10%
OADC enrichment. A volume of 50 μL of the stock solu-
tion of UA (compound A) and 50 μL of OA (compound B)
were added simultaneously to the well, having been
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the bacterial suspension adjusted to a McFarland 1 tube
and diluted in a ratio of 1:10. Controls for each compound
were prepared by adding 50 μL of the corresponding stock
solution, 50 μL of the culture medium and 100 μL of the
same adjusted bacterial suspension. Control for bacterial
growth included 100 μL of 7H9 broth and 100 μL of the
bacterial suspension. Plates were incubated for 5 days at
37°C; after this period, 20 μL of alamar blue solution (Trek,
USA) and 12 μL of 20% Tween 80 sterile solution were
added to the wells, leaving the plates overnight at 37°C.
A relative fluorescent unit (RFU) was determined in a
fluorometer (Fluoroscank FL, Labsystem). Analysis of
pharmacological interactions were carried out by the X/Y
quotient analysis, where X represents the RFU value of the
drug combination and Y, the lowest RFU value obtained
with both pure compounds. Activity was considered syner-
gistic when the X/Y value was <0.5 and additive when X/Y
was >0.5 and <1.0. Activity was considered absent when
X/Y was 1–2 and antagonistic when X/Y was >2.
Cytotoxicity and intracellular antitubercular activity
tested in vitro
Cytotoxicity of the triterpenic acids was evaluated by the
trypan blue exclusion assay. Briefly, 24 well tissue culture
plates were seeded with murine macrophages J774A.1
(ATCC HB-197) in 1 mL of Dulbecco’s modified Eagle’s
medium (DMEM) with 10% fetal bovine serum (FBS) with
antibiotics to reach a confluence of at least 80%. Cells were
treated with four concentrations of the pure compounds,
taking the minimal inhibitory concentration (MIC) of each
one as reference. These dilutions were prepared in DMEM
with 1% FBS without antibiotics (hereafter denoted wor-
king solutions). Before treatment, the wells were washed
three times with warm Hank’s balanced salt solution
(HBSS), and 1 mL of working solution was added to each
of the corresponding wells. The percentage of viable cells
was determined prior to treatment and after 24, 48, 72,
and 96 hrs by adding trypan blue solution to reach a final
concentration of 0.2% per well; at least 200 cells per well
were counted. Those compound concentrations that after
96 hrs of incubation did not affect cell viability <90% (IC90)
were considered non-toxic.
Antimycobacterial intracellular activity was tested in
the macrophage cell line J774A.1 infected with M. tuber-
culosis H37Rv and the MDR clinical isolate MTY147,
using two non-toxic concentrations: high (12.5 μg mL-1
for OA and 6.25 μg mL-1 for UA) and low (1.25 and
0.625 μg mL-1 for OA and UA, respectively). For this
purpose, log phase growth of M. tuberculosis H37Rv in
Middlebrook 7H9 broth with 10% OADC was washed
twice with HBSS and adjusted in DMEM with 1% FBS
to reach a bacterial macrophage multiplicity of infection
of 10:1. Macrophages were incubated with the bacilli for2 hrs and non-phagocytosed organisms were removed by
three washes with warm HBSS. Then, 1 mL of UA or OA
at different concentrations alone or in combination was
added to the infected macrophages at 37°C in a 5% CO2
atmosphere; after 24, 48, 72, and 96 hrs of treatment, the
cells from the corresponding wells were lysed with 0.5 mL
of 0.25% sodium dodecyl sulfate (SDS) for 3 min and later
0.5 mL of 5% bovine serum albumin (BSA) was added.
Control cells contained only the culture medium. Viable
bacteria were determined by quantification of colony-
forming units (CFU) by plating dilutions of the macro-
phage lysates on Middlebrook 7H11 agar with 10% BSA.
Experimental model of progressive pulmonary TB
in BALB/c mice
The antitubercular activity in-vivo of both compounds
administered together was determined by using an ex-
perimental model of progressive pulmonary TB that was
previously described [26]. Briefly, male BALB/c mice at
6–8 weeks of age were used. M. tuberculosis H37Rv or
MDR clinical isolate (CIBIN/UMF 15:99, strain resistant
to rifampicin, ethambutol, streptomycin, pyrazinamide and
isoniazid) was cultured in Proskauer and Beck medium as
modified by Youmans. After 1 month of culture, the myco-
bacteria were harvested and adjusted to 2.5×105 cells in
100 μL of phosphate buffered saline (PBS), aliquoted and
maintained at −70°C until use. Before testing, the bacilli
were recounted and the viability was determined.
To induce pulmonary TB, mice were anesthetized with
sevofluorane, and 2.5×105 viable mycobacteria suspended
in 100 μL of PBS were administered intratracheally (i.t.)
using a rigid stainless steel cannula and maintained in
a vertical position until spontaneous recovery. Infected
mice were housed in groups of five in cages fitted with
micro-isolators.
Ethics statement
All procedures were performed in a laminar flow cabinet
in bio-safety level III facilities. The study with animals
was performed according to guidelines of the local Ethical
Committee for Experimentation in Animals in Mexico
(Ministry of Agriculture, NOM-062-ZOO-1999, Mexico)
modified in 2001 and was approved by the Institutional
Animal Care and Use Committee, 236. An experimental
protocol used in this study was approved by the Comisión
Nacional de Investigación Científica (CNIC, IMSS 2006-
785-025-028).
Drug administration
Animals surviving 60 days after infection were randomly
allocated to the required treatment groups. Thus, treat-
ment began 60 days after infection, and groups of these
animals were sacrificed at 1- and 2-month intervals. All
data points are the means [± standard deviation (SD)] of
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tion of the appropriate dose was calculated according to
the MIC determined in-vitro (drug concentration effi-
cient to kill 1×106 bacilli) by adjusting the drug concentra-
tion to the estimated number of bacilli in the lungs of the
mice after 2 months of infection; this drug amount was tri-
pled, considering its dilution after absorption and systemic
distribution after subcutaneous (s.c.) administration. As
shown later in the results section, the pharmacological
interaction assay demonstrated synergism of between the
two triterpenoids. Thus, 5 mg kg-1 of each triterpenic acid
was dissolved in ultra-pure olive oil (Sigma) and a total vo-
lume of 100 μL was administered s.c.: three parts of UA
(75 μg) and one part of OA (25 μg); this mixture was ad-
ministered 3 times/week for 30 and 60 days. This dose was
also used to supplement conventional chemotherapy in
order to discover whether it might synergize and shorten
the required duration of chemotherapy. Thus, we treated a
group of mice with conventional antibiotics (ABS): a com-
bination of 10 μg kg-1 rifampicin, 10 μg kg-1 isoniazid, and
30 μg kg-1 pyrazinamide dissolved in isotonic saline solu-
tion (ISS) and intragastrically (i.g.) administered daily;
another group was treated with this conventional
chemotherapy scheme plus the mixture of both terpe-
noids. The control group corresponded to infected ani-
mals receiving only the vehicle (olive oil) s.c. and ISS by
the i.g. route. Groups of six animals were euthanized at
7, 14, 30 and 60 days post-treatment in two independent
experiments.
Assessment of colony-forming units (CFU) in infected lungs
and preparation of tissue for histology and morphometry
One lung was immediately frozen by immersion in li-
quid nitrogen and used for colony counting, while the
remaining lung was perfused with 10% formaldehyde
and used for histopathological analysis. Frozen lungs were
disrupted in a Polytron homogenizer (Kinematica, Lucerne,
Switzerland) in sterile 50 mL tubes containing 3 mL of iso-
tonic saline solition (ISS). Four dilutions of each hom-
ogenate were spread on duplicate plates containing Bacto
Middlebrook 7H10 agar (Difco Lab code 0627-17-4)
enriched with OADC also from Difco (code 07-22-64-0).
Incubation time was 21 days. Four lungs per each group
from different animals at each time point in two different
experiments were studied.
For the histological study, after 2 days of fixation,
parasaggital sections were taken through the hilus, and
these were dehydrated and embedded in paraffin, sec-
tioned at 5 μm and stained with hematoxylin and eosin
(H&E). The percentage of lung surface affected by pneu-
monia was measured by using an image analysis system
(Q-Win 500 W Leica). Measurements were carried out in
blinded fashion and the data are expressed as the mean of
four animals’ ± SD.Real time PCR analysis of cytokines in lung homogenates
Total RNA was isolated from cell suspensions using four
lungs from the same number of different animals per
group after 1 and 2 months of treatment (3 and 4 months
of infection). The lung was placed in 2 mL of RPMI
medium containing 0.5 mg mL-1 collagenase type 2
(Worthington, NJ, USA), and incubated for 1 h at 37°C. It
was then passed through a 70 μm cell sieve, crushed with
a syringe plunger and rinsed with the medium. The cells
were centrifuged, the supernatant was removed, and red
cells were eliminated with a lysis buffer. After counting,
350 μL of RLT buffer were added to 5×106 cells and RNA
was extracted by the RNeasy Plant Mini Kit (Qiagen, Inc.,
USA) according to the manufacturer’s instructions. The
quality and quantity of RNA were evaluated through spec-
trophotometry (260/280) and on agarose gels. Reverse
transcription of mRNA was performed using 5 μg RNA,
oligo-dt, and the Omniscript kit (Qiagen, Inc). Real-time
PCR was performed using the 7500 Real time PCR system
(Applied Biosystems, USA) and the QuantiTect SYBR
Green Master Mix kit (Qiagen). Standard curves of quanti-
fied and diluted PCR product as well as of negative con-
trols were included in each PCR run. Specific primers were
designed using the Primer Express (Applied Biosystems,
USA) program for the following targets: Glyceraldehyde-
3-phosphate dehydrogenase (G3PDH): 5′-cattgtggaaggg
ctcatga-3′, 5′-ggaaggccatgccagtgagc-3′; inducible Nitric
oxide synthase (iNOS): 5′-agcgaggagcaggtggaag-3′, 5′-catt
tcgctgtctccccaa-3′; TNF-α: 5′-tgtggcttcgacctctacctc-3′, 5′-
gccgagaaaggctgcttg-3′, and Interferon gamma (IFN-γ):
5′-ggtgacatgaaaatcctgcag-3′, 5′-cctcaaacttggcaatactcatga-3′.
The following cycling conditions were employed: an ini-
tial denaturation at 95°C for 15 min, followed by 40 cycles
at 95°C for 20 sec, at 60°C for 20 sec, and at 72°C for
34 sec. Quantities of the specific mRNA in the sample
were measured according to the corresponding gene-
specific standard. The mRNA copy number of each cyto-
kine was related to 1 million copies of mRNA encoding
the G3PDH gene.
Statistics analysis
A one-way analysis of variance (ANOVA) and the Student
t test were used to compare CFU and morphometry deter-
minations in infected mice treated with terpenoids and in
non-treated control animals. A difference of P <0.05 was
considered significant.
Results
In vitro determination of antimycobacterial activity
and synergism of UA and OA
Table 1 shows the MICs values of UA and OA deter-
mined by the MABA assay. When the reference strain
H37Rv was used, UA showed a MIC of 25 μg mL-1 and
OA 50 μg mL-1. Both compounds were also effective
Table 1 In vitro antimycobacterial activity of Ursolic acid
(UA) and Oleanolic acid (OA) tested by MABA assay
M. tuberculosis strain MIC (μg mL-1)
(ATCC) UA OA UA/OA
H37Rv (27294) 25 50 12.5
INH-R (35822) 25 25 25
RIF-R (35838) 25 25 25
EMB-R (35837) 25 25 25
STR-R (35820) 12.5 50 25
DR clinical isolates
MMDO 25 50 ND
MTY147 25 50 ND
Non-tuberculous mycobacterium
M. chelonae 100 100 100
M. avium 100 100 100
M. smegmatis >200 100 100
M. fortuitum 100 100 100
M. simiae >200 100 100
H37Rv: sensitive strain to INH, RIF, EMB, STR, and pyrazinamide; RIF-R:
rifampicin-resistant to H37Rv; STR-R: streptomycin-resistant to H37RV; INH-R:
isoniazid-resistant to H37Rv and EMB-R: ethambutol-resistant to H37Rv;
MMDO: strain resistant to isoniazid and ethambutol; MTY 147: strain resistant
to isoniazid, rifampicin, ethambutol and ethionamide. MIC: minimum inhibitory
concentration. Data are means of three determinations. UA: ursolic acid; OA:








Figure 2 In vitro synergistic effect of Ursolic acid (UA) and
Oleanolic acid (OA). One half of the in vitro MIC of UA and OA
alone or in combination were incubated with M. tuberculosis H37Rv
and RFU were recorded at the end of the incubation period; the X/Y
quotient analysis was applied to establish the type of pharmacological
interaction between these compounds, where X represents the RFU
value obtained with the combination of both compounds, and Y is the
RFU value of the compound that presented the lowest value, when
alone. Synergy was considered when the X/Y value was <0.5.
Jiménez-Arellanes et al. BMC Complementary and Alternative Medicine 2013, 13:258 Page 5 of 11
http://www.biomedcentral.com/1472-6882/13/258against the monoresistant strains (isoniazid-, rifampicin-
and ethambutol-resistant) with a MIC of 25 μg mL-1.
The streptomycin-resistant M. tuberculosis H37Rv strain
was more sensitive to UA (MIC = 12.5 μg mL-1) but less
sensitive to OA (MIC = 50 μg mL-1). The mixture of
both compounds showed a MIC = 12.5 μg mL-1 against
the H37Rv strain. Terpenoids showed a lesser effect against
non-tuberculous mycobacteria, with MICs ranged be-
tween 100 to >200 μg mL-1. Interestingly, the combined
effect of UA and OA in vitro exhibited synergistic ac-
tivity at a proportion of 0.5 MIC of OA (25 μg mL-1)
and 0.5 MIC of UA (12.5 μg mL-1), with an X/Y value
of <0.5 (Figure 2).
Cytotoxicity and intracellular activity of UA and OA
Considering the in vitro MIC values found for each
compound, the intracellular activity of both triterpenoids
was evaluated in a macrophage model for both Mycobac-
terium strains (H37Rv and the MDR clinical isolate).
The cytotoxicity of these compounds revealed that at
concentrations >20 μg mL-1, cell death was above 30%
and below 18. Two concentrations below this concentra-
tion were used for macrophage treatment: the first was
1/4 of the MIC and second 1/40 of the MIC of each
compound (Figure 3). We observed that at a high con-
centration (1/4 MIC) with both Mycobacterium strains
there was a statistically significant CFU reduction afterUA and OA treatment, but when both compounds were
added together greater elimination of bacilli was observed
(Figure 3A). Even at a lower concentration (1/40 MIC),
there was an efficient antimycobacterial effect of either UA
or OA; in the case of the M. tuberculosis H37Rv strain, the
combined effect of UA and OA at a lower concentrations
was still very effective, while for the MDR strain, it was less
effective (Figure 3B).
Effects of triterpenic acids in vivo on lung bacillary load,
histopathology and cytokine gene expression
In comparison with non-treated control mice, animals
infected with the drug-sensitive H37Rv strain treated
with both OA and UA showed a significant decreased
number of live bacilli in the lungs after 1 and 2 months
of treatment (Figure 4A). These results in bacillary loads
correlated well with the morphometric observations; this
showed a significant decrease of the lung area affected
by pneumonia in treated animals as compared with those
of the non-treated control group (Figure 4B).
Since UA and OA have diverse immunoregulatory ac-
tivities [19,22], the expression of genes encoding IFN-γ,
TNF-α and iNOS was determined by real time PCR.
Figure 4C illustrates that animals treated with UA/OA
exhibited a higher (but not significantly) expression of
both cytokines and a significantly higher expression of
iNOS than non-treated control animals.
Animals infected with the drug-sensitive H37Rv strain
and treated with both terpenoids in combination with
conventional chemotherapy showed pulmonary bacilli
burdens and tissue damage similar to that seen in animals
treated with chemotherapy only (Figure 5A and 5B). Thus,
Figure 3 Intracellular activity of Ursolic acid (UA), Oleanolic acid (OA) and their combination against M. tuberculosis H37Rv and MDR
clinical isolate in the macrophage cell model. Macrophages (cell line J774A.1) were infected (MOI 10:1) with drug-sensitive H37Rv or DR strain
and treated with UA, OA, or both together at two concentrations, upper (panel A) and lower (panel B). After several time points, cells were lysed
and intracellular bacillus colony forming units (CFU) were determined. In comparison with non-treated control cells, each terpenoid alone had
significant antimycobacterial activity at high or low treatment concentrations, but when OA and UA were incubated together, the
















































































Figure 4 Effect of Ursolic acid (UA)/Oleanolic acid (OA) administration on bacterial loads, pathology and cytokine expression during
advanced disease in lungs from mice infected with the M. tuberculosis H37Rv strain. (A) UA/OA administration (white bars) starting 60 days
after infection decreased pulmonary bacterial loads when compared with those of control mice (black bars). (B) UA/OA-treated mice (white bars)
at days 30 and 60 post-treatment showed less pneumonic area than the control group. (C) UA/OA treatment induced a slightly higher expression
of TNF-α and IFN-γ, and a significantly higher expression of inducible iNOS at day 60 when compared with non-treated control mice. ABS:
correspond to 10 μg kg-1 rifampicin, 10 μg kg-1 isoniazid and 30 μg kg-1 pyrazinamid. Each point corresponds to the mean ± Standard deviation (SD) of
groups of four mice. Asterisks represent the statistical significance between groups (*P <0 · 05; **P <0 · 01).

































































































Figure 5 Effect of combined treatment with chemotherapy and Ursolic acid (UA)/Oleanolic acid (OA). (A) Shows the number of Colony-forming
units (CFU) in lungs of mice infected with M. tuberculosis H37Rv sensitive strain. Beginning on day 60 after infection, mice were treated either with
conventional chemotherapy alone (gray bars) or with conventional chemotherapy in combination with UA/OA 3 times/week (white bars). Also shown
are values for control (untreated) mice (black bars). (B) The effect of combined treatment on the percentage of lung surface affected by pneumonia.
(C) Combined treatment induced significantly higher expressions of TN-α, IFN-γ, and iNOS. Each point corresponds to the mean ± Standard deviation (SD)
of four mice groups. Asterisks represent the statistical significance between groups (*P <0 · 05; **P <0 · 01).
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combined treatment induced a higher expression of
IFN-γ, TNF-α, and iNOS than was seen in the group
treated only with antibiotics, or in the non-treated control
group (Figure 5C).
Due to the emergence of MDR strains and given the
improved disease course in UA/OA-treated mice in-
fected with the drug-sensitive H37Rv strain, we decided
to study whether this therapy has the ability to produce
similar beneficial effects on mice infected with a M. tu-
berculosis clinical isolate resistant to all first-line antibiotics
during late active disease. In comparison with control
animals, MDR clinical isolate-infected mice treated with
UA/OA showed significantly lower lung bacillary loads
at 1 month of treatment and reduced, but not signifi-
cantly, lung bacillary loads at 2 months (Figure 6A). Simi-
larly, improved lung histopathology was observed, with
a significant decrease of pneumonia (Figure 6B) at 30
and 60 days of treatment, as compared with the group
of non-treated mice (P <0 · 01). The determination of
cytokine gene expression by real-time PCR showed
higher IFN-γ expression in the lungs of UA/OA-treated
animals (Figure 6C), with statistical significance at 30 days
(P <0 · 05) of treatment. Thus, in addition to modest
antimycobacterial activity, both terpenoids also possess
immunotherapeutic effects.Discussion
UA (3β-hydroxy-urs-12-en-28-oic-acid) and its isomer,
OA (3β-hydroxy-olea-12-en-28-oic acid) are triterpenoids
compounds that are widely distributed in the plant king-
dom, in medicinal herbs, and are a common component
of the human diet [27]. There are comprehensive reports
on their biological activities and beneficial effects in vari-
ous diseases, including infectious diseases [16,27]. In this
regard, there are several reports of their significant anti-
mycobacterial activity when they are primarily purified
from diverse plants [9,11,28]. Indeed, the present study
comprises part of a research program that involves an
ethnopharmacological screening of Mexican medicinal
plants in a search for activity against M. tuberculosis. Our
previous studies showed that UA and OA were in part re-
sponsible for the antimycobacterial activity from L. hispida
(a widely distributed, ornamental Mexican plant used in
folk medicine to treat TB) and C. tepejilote (a tropical
plant from Southern Mexico used to treat respiratory
diseases) [6,8]. The results presented here confirm and
extend these studies, showing that purified UA and OA
have in vitro antimycobacterial activity against fully drug-
sensitive and monoresistant H37Rv strains, as well as
several MDR clinical isolates and to a lesser degree, non-
tuberculous mycobacteria. Our results on the in vitro ac-






















































































Figure 6 Effect of Ursolic acid (UA)/Oleanolic acid (OA) treatment on lung bacillary loads, pathology and cytokine expression during
late disease produced by the multidrug-resistant (MDR) clinical isolate. (A) UA/OA mixture was administered 3 times per week (white bars)
for 2 months, starting at day 60 post-infection with the MDR clinical isolate (CIBIN/UMF 15:99), decreased bacterial loads when compared with
non-treated control animals (black bars). (B) These UA/OA-treated mice displayed a lesser pneumonia area than the control animals. (C) Administration
of both terpenoids induced higher expression of proinflammatory cytokines and inducible iNOS. Each point corresponds to the mean ± Standard
deviation (SD) of groups of four mice. Asterisks represent statistical significance between groups (*P <0 · 05; **P <0 · 01).
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50 μg mL-1 when evaluated by the radiorespirometric
Bactec 460, and 31.0 and 41.9 μg mL-1 by MABA assay;
while MIC values reported for OA were 50 μg mL-1 when
tested by the radiorespirometry method and 30.0, 28.7,
and 25 μg mL-1 by MABA [9,29-32]. Both triterpenic acids
exhibited less activity against non-tuberculous mycobac-
teria, with the MIC value of 100 μg mL-1. This is in fact
modest antimycobacterial activity. However, one major
point of traditional medicine is the use of herb mixtures,
which could be more effective than a single product for
producing the desired effects [28]. UA and OA are iso-
mers, and our results showed that the combination of
both produced in vitro intracellular and in vivo syn-
ergistic effects. Although the molecular mechanism of the
antimycobacterial activity has not yet been determined, it
has been proposed that UA and OA can produce signifi-
cant abnormalities in the bacterial cell wall [9,13]. Both
terpenoids have efficient antilipidic activity on eukaryotic
cells [33], and perhaps this activity can also affect myco-
bacteria producing damage on the complex cell envelope,
which is rich in lipids.
Mycobacterial infections are controlled by the activa-
tion of macrophages through type 1 cytokine production
by T cells [34-36]. IFN-γ and TNF-α are essential for this
process because they promote macrophage activation
and iNOS expression. This is clearly observed in ourBALB/c mouse model, which is based on infection via
the trachea with a high dose of M. tuberculosis H37Rv
[26,37]. In this model, there is an initial phase of partial
resistance dominated by Th1 cytokines plus TNF-α and
the expression of iNOS, followed by a late phase of pro-
gressive disease after 1 month of infection, characterized
by a lower expression of IFN-γ, TNF-α, or iNOS, progres-
sive pneumonia, extensive interstitial fibrosis, high bacil-
lary counts and very high levels of immunosuppressive
factors such as TGF-β1 and Prostaglandin E-2 (PGE2)
[26,37,38]. This BALB/c tuberculosis model has been
used extensively to test different forms of therapy [39-41],
thus confirming that it is highly suitable for exploring the
efficiency of new natural drugs or immunotherapy based
on the airway infection route, which is the most common
pathway of infection in humans and the highest rate of
bacterial multiplication in the lung correlates with the
extent of tissue damage (pneumonia) and death of infected
animals [26].
Although contrasting differences in immune responses
have been observed that depend on triterpenic con-
centrations and the biological status of the target cells
used in different experimental systems [42], it has been
reported that UA and OA stimulate IFN-γ production
[43], and also upregulate iNOS and TNF-α expression
through NF-kB transactivation in murine resting macro-
phages [19,20]. More recently, it has been demonstrated
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IL-12, polarizing the Th-1 response [44]. Tuberculous ani-
mals treated with both triterpenic acids showed a higher
expression of IFN-γ, TNF-α, and iNOS than non-treated
control animals, or even than sick mice successfully treated
with conventional chemotherapy, suggesting that UA and
OA exert an effect as immunostimulating factors that can
restore the protective antimycobacterial cytokine pattern
during advanced disease, producing a significant decrease
of bacillus loads and tissue damage.
Suppression of T-cell responses to mycobacterial anti-
gens is a consistent feature of TB [45], and in vitro and
in vivo observations indicate that TGF-β participates in
these effects [46-50]. It is well established that M. tuber-
culosis and its components are efficient inducers of the
TGF-β1 production by macrophages and this cytokine is
a significant factor in the suppression of cell-mediated
immunity (CMI) and in the induction of fibrosis [49].
Another molecule that is also produced in high amounts
during progressive TB and has CMI suppressing acti-
vities is PGE-2. In fact, TGF-β and PGE2 share many
immunomodulatory functions, such as the inhibition of
IFN-γ, interleukin 2 (IL-2) and IL-12 production [50,51]
and macrophage deactivation, suppressing TNF-α and
iNOS production [52,53]. We have shown, in this experi-
mental model of pulmonary TB, that by blocking TGF-β
activity by the administration of its soluble receptor type
3 or betaglycan, while simultaneously suppressing PGE-2
production by the administration of niflumic acid, a spe-
cific cyclooxygenase type 2 (COX-2) blocker, we can
produce a significant therapeutic benefit associated with
restoration of the protective cytokine pattern (41). Inter-
estingly, UA and OA antagonize TGF-β1 activity by
blocking the binding of its specific receptor [21,22],
which is the same function as the soluble receptor
type 3 or betaglycan. Moreover, UA and OA also sup-
press prostaglandin production by blocking the binding
of c-Jun to the response element of the COX-2 promoter,
thus preventing the transcription of this enzyme [54], or
by irreversible inhibition of secretory phospholipase A2
[55,56]. Thus, the restoration of the protective cytokine
pattern observed in animals treated with UA or OA could
be attributable to the modulating effect that they have on
TGF-β and COX-2 activity. However, there are published
reports indicating contrary activities that are receptor-
and mouse strain- dependent [57]. Thus, as mentioned
previously [58] with respect to the control of the inflam-
matory response, these triterpenoids can have both posi-
tive and negative effects, and further evaluations of their
effect on the biological status of target cells or tissues in
health and disease are necessary.
It is noteworthy that to date, there are no studies that
describe the antituberculous effect of the pure com-
pounds of medicinal plants. Thus, to our knowledge, thisstudy constitutes the first that focuses on evaluating
the antituberculous activity in vivo of this type of
compound. Moreover, we recently published data on
the toxicity in-vivo of the UA/OA mixture; it is prac-
tically innocuous when evaluated by the s.c. route in
acute (LD50 > 300 mg kg
-1) and subacute (13 mg kg-1
repeated-dose during 28-day) assays in BALB/c mice
[59]. Therefore, these compounds can be considered
potential candidates to the treatment of TB.
Conclusion
Our results showed that UA and OA obtained from me-
dicinal plants used in Mexican traditional medicine to
treat TB have modest antimycobacterial and some im-
munoregulatory activities that permit the control of pul-
monary TB in mice, indicating that research on natural
products can produce novel antibiotic and/or immuno-
therapeutic agents useful for the treatment of this sig-
nificant infectious disease.
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